Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

H Nabi; B Glintborg; A G Loft; O Hendricks; J K Pedersen; S A Just; R Ahmed; K Danebod; H L Munk; A Colic; A Linauskas; D V Jensen; L B Christensen; N Manilo; N Lomborg; S Kristensen; F Mehnert; N S Krogh; M L Hetland

Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

H Nabi, B Glintborg, A G Loft, O Hendricks, J K Pedersen, S A Just, R Ahmed, K Danebod, H L Munk, A Colic, A Linauskas, D V Jensen, L B Christensen, N Manilo, N Lomborg, S Kristensen, F Mehnert, N S Krogh, M L Hetland

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	50
Issue number	Suppl. 130
Pages (from-to)	14-15
Number of pages	2
ISSN	0300-9742
Publication status	Published - Aug 2021
Event	38th Scandinavian Congress of Rheumatology - Scandic Parken, Ålesund, Norway Duration: 1 Sept 2021 → 4 Sept 2021 Conference number: 38

Conference

Conference	38th Scandinavian Congress of Rheumatology
Number	38
Location	Scandic Parken
Country/Territory	Norway
City	Ålesund
Period	01/09/2021 → 04/09/2021

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Nabi, H., Glintborg, B., Loft, A. G., Hendricks, O., Pedersen, J. K., Just, S. A., Ahmed, R., Danebod, K., Munk, H. L., Colic, A., Linauskas, A., Jensen, D. V., Christensen, L. B., Manilo, N., Lomborg, N., Kristensen, S., Mehnert, F., Krogh, N. S., & Hetland, M. L. (2021). Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology, 50(Suppl. 130), 14-15.

Nabi, H ; Glintborg, B ; Loft, A G et al. / Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. In: Scandinavian Journal of Rheumatology. 2021 ; Vol. 50, No. Suppl. 130. pp. 14-15.

@article{baad2566859b4ab68fc65b4dcbaed299,

title = "Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry",

author = "H Nabi and B Glintborg and Loft, {A G} and O Hendricks and Pedersen, {J K} and Just, {S A} and R Ahmed and K Danebod and Munk, {H L} and A Colic and A Linauskas and Jensen, {D V} and Christensen, {L B} and N Manilo and N Lomborg and S Kristensen and F Mehnert and Krogh, {N S} and Hetland, {M L}",

year = "2021",

month = aug,

language = "English",

volume = "50",

pages = "14--15",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "Suppl. 130",

note = "38th Scandinavian Congress of Rheumatology ; Conference date: 01-09-2021 Through 04-09-2021",

}

Nabi, H, Glintborg, B, Loft, AG, Hendricks, O, Pedersen, JK, Just, SA, Ahmed, R, Danebod, K, Munk, HL, Colic, A, Linauskas, A, Jensen, DV, Christensen, LB, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, NS & Hetland, ML 2021, 'Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry', Scandinavian Journal of Rheumatology, vol. 50, no. Suppl. 130, pp. 14-15.

Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. / Nabi, H; Glintborg, B; Loft, A G et al.
In: Scandinavian Journal of Rheumatology, Vol. 50, No. Suppl. 130, 08.2021, p. 14-15.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

AU - Nabi, H

AU - Glintborg, B

AU - Loft, A G

AU - Hendricks, O

AU - Pedersen, J K

AU - Just, S A

AU - Ahmed, R

AU - Danebod, K

AU - Munk, H L

AU - Colic, A

AU - Linauskas, A

AU - Jensen, D V

AU - Christensen, L B

AU - Manilo, N

AU - Lomborg, N

AU - Kristensen, S

AU - Mehnert, F

AU - Krogh, N S

AU - Hetland, M L

N1 - Conference code: 38

PY - 2021/8

Y1 - 2021/8

UR - https://doi-org.auh.aub.aau.dk/10.1080/03009742.2021.1951065

M3 - Conference abstract in journal

SN - 0300-9742

VL - 50

SP - 14

EP - 15

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - Suppl. 130

T2 - 38th Scandinavian Congress of Rheumatology

Y2 - 1 September 2021 through 4 September 2021

ER -

Nabi H, Glintborg B, Loft AG, Hendricks O, Pedersen JK, Just SA et al. Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology. 2021 Aug;50(Suppl. 130):14-15.

Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Conference

AUB Link

Other files and links

Cite this